Astrazeneca plc (AZN) is slightly undervalued and Johnson & Johnson (JNJ) is overvalued.
Against our estimates of intrinsic value, AZN trades at the wider discount: a margin of safety of +7%, against -32% for JNJ.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.4% (average of 3 methods) values the shares at $180.20; the price of $168.37 is 7% below that value, and 82% of that value comes from beyond year five.
Leak Score 59/100 on 3 of 12 signals
Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $204.15; the price of $269.19 is 32% above that value, and 83% of that value comes from beyond year five.
Leak Score 50/100 on 9 of 12 signals
| Metric | AZN | JNJ |
|---|---|---|
| Verdict | Slightly undervalued | Overvalued |
| Price | $168.37 | $269.19 |
| Intrinsic value | $180.20 | $204.15 |
| Margin of safety | +7% | -32% |
| Leak Score | 59/100 (3/12) | 50/100 (9/12) |
| Market cap | $261.1B | $648.7B |
| Revenue growth, 5 years | 16.3% | 2.7% |
| Operating margin | 22.4% | 27.0% |
| Net margin | 17.0% | 21.5% |
| Return on equity | 22.0% | 25.7% |
| Debt to equity | 0.64 | 0.58 |
| P/E | 25.2x | 31.2x |
| Forward P/E | 14.6x | 21.2x |
| P/B | 5.2x | 7.6x |
| Dividend yield | 2.0% | 2.0% |